Simvastatin attenuates inflammatory process on LPS-induced acute lung injury in mice

Respir Physiol Neurobiol. 2023 Mar:309:104002. doi: 10.1016/j.resp.2022.104002. Epub 2022 Dec 21.

Abstract

Acute lung injury (ALI) is a disease of high prevalence and is characterized by the excessive production of inflammatory mediators in the lungs of people sick. Inflammation is the major characteristic of ALI and studies report that inhibition of inflammatory cytokines could be an alternative treatment. Statins such as Simvastatin (SV) are known to their use for cholesterol reduction but also for inflammatory and immunoregulatory processes. In this study, we evaluated the effects of SV on LPS-induced alveolar macrophages and in ALI mice model. Our study has demonstrated the protective effects of SV on LPS-activated alveolar macrophages RAW 264.7 and LPS-induced ALI in mice. SV treatment significantly inhibited the alveolar macrophages activation by decreasing the iNOS, IL-1β, and IL-6 gene expression in vitro and in vivo. The treatment also decreased the inflammatory cells migration and the cytokines gene expression. Our findings suggest that SV can act as an anti-inflammatory agent for acute lung injury.

Keywords: Acute lung injury; Cytokines; Inflammation; Macrophages; Neutrophils; Simvastatin.

MeSH terms

  • Acute Lung Injury* / chemically induced
  • Acute Lung Injury* / drug therapy
  • Acute Lung Injury* / metabolism
  • Animals
  • Cytokines / metabolism
  • Lipopolysaccharides* / metabolism
  • Lipopolysaccharides* / toxicity
  • Lung / metabolism
  • Mice
  • Simvastatin / adverse effects

Substances

  • Lipopolysaccharides
  • Simvastatin
  • Cytokines